Coronary disease & ACSCohort study
Prognostic impact of residual inflammatory and triglyceride risk in statin-treated patients with well-controlled LDL cholesterol and atherosclerotic cardiovascular disease
- Cohort study
Authors' conclusion
In statin-treated patients with well-controlled LDL-C undergoing PCI, residual inflammatory risk-alone or in combination with residual TG risk-was associated with a higher incidence of MACE
Study context
- Population
- Statin-treated patients with LDL-C < 70 mg/dL undergoing percutaneous coronary intervention (PCI), 2012–2022
- Participants
- 9,446 patients
- Exposure
- Residual TG and/or inflammatory risk vs no residual risk
- No residual riskn = 5,339reference
- Residual TG riskn = 555
- Residual inflammatory riskn = 3,009
- Residual TG and inflammatory riskn = 543
- Outcome
- MACE:
- All-cause mortality
- MI
- Stroke
- Follow-up
- 1 year
Main finding
As reported in the abstract
MACE
- Residual inflammatory or combined risk vs no residual risk: significantly higher hazard of major adverse cardiovascular events (MACE) after multivariable adjustment, mainly driven by all-cause mortality
- Residual TG risk vs no residual risk: no significant difference
Observational data: associations, not effects.
Original publication
Prognostic impact of residual inflammatory and triglyceride risk in statin-treated patients with well-controlled LDL cholesterol and atherosclerotic cardiovascular disease. Eur J Prev Cardiol. Published 20 March 2025. doi:10.1093/eurjpc/zwaf112
Summarised from the published abstract; every number is checked against it